Genitourinary Cancers

Dr. Sia Daneshmand earned his medical degree at the University of California, Davis and completed his residency at the University of Southern California (USC) followed by a two-year fellowship in Urologic Oncology at the USC/Norris Comprehensive Cancer Center. He spent almost 6 years at Oregon Health and Science University and was then recruited to USC Institute of Urology in 2010 as Director of Urologic Oncology. He is currently an Associate Professor of Urology with Clinical Scholar designation and serves as director of clinical research as well as the urologic oncology (SUO) fellowship director. Dr. Daneshmand’s main interests include bladder cancer, advanced kidney cancer and testicular cancer. He has extensive experience in urinary diversion and reconstruction following radical cystectomy as well as nerve-sparing retroperitoneal lymph node dissection (RPLND) following chemotherapy for advanced testis cancer. He is one of the highest volume surgeons for these diseases inthe country. He also has extensive experience in the management of advanced kidney cancers with vena caval tumor thrombus involvement, as well as prostate cancer, retroperitoneal sarcomas and surgeries requiring replacement of the great vessels. His main research interests focus on the use of pathways to improve peri-operative outcomes following radical cystectomy, use of serum and molecular markers and new technologies in diagnosis and management of bladder cancer, as well as functional outcomes following orthotopic urinary diversion.  He is a leading authority on enhanced recovery after surgery (ERAS) following radical cystectomy and his protocol has significantly reduced hospital stay while improving the patient experience. He serves on the editorial board of the Journal of Urology, Bladder Cancer Journal, Current Opinions in Urology, the scientific advisory board of Bladder Cancer Advocacy Network (BCAN) as well as the AUA/SUO Guideline Committee on non-muscle invasive bladdercancer as well as testicular cancer. He is a member of Alpha Omega Alpha medical honor society and has been designated one of the “America’s Top Cancer Doctors” for the past 8 consecutive years.   He is an active member of the Society of Urologic Oncology, has presented over 300 abstracts at scientific meetings and has authored over 200 peer-reviewed articles, reviews, and book chapters. Dr. Kevin Chan earned his medical degree at the University of Southern California and completed his urology training at the University of Southern California.  Following his training, he joined the urology faculty at City of Hope Cancer Center in Duarte, California.  He is currently a Clinical Associate Professor of Surgery in the Division of Urology and the Head of Reconstructive Urology at City of Hope Cancer Center.  At City of Hope, Dr. Chan has established one of the largest programs in continent urinary diversion using robot-assisted laparoscopic radical cystectomy for the treatment of bladder cancer. In addition to his clinical practice, Dr. Chan conducts research in surgical techniques and postoperative pathways that will help minimize complications and improve outcomes in the treatment of bladder cancer. He has vast experience in the surgical treatment of male urinary incontinence and has created a database at City of Hope with the goal of improving surgical techniques used to treat male urinary incontinence. Dr. Chan's research interests also include the development of novel diagnostic techniques to improve the detection and progression of prostate cancer.

• New Imaging Techniques in Prostate Cancer.- Targeted ablative therapies for prostate cancer.-  Prostate cancer markers.-  Prognostic value of CTC’s in urologic cancers.- Management of Small Renal Masses.-  Advances in the Treatment of Metastatic Renal Cell Carcinoma.-Imaging in urologic cancers .-   Molecular prognostication in Bladder cancer.-  Early cystectomy for high risk non-muscle invasive disease.-  Care-coordination pathway after radical cystectomy.-  Current role of checkpoint inhibitors in urologic cancers.- ) The Cancer Genome Atlas Project.-  Prognostic models in germ cell tumors.- Modern management of testicular cancer.